Neutropenia

Acute neutropenia

Chronic neutropenia

Neutropenia and Lymphocytopenia

Neutropenia caused by intrinsic defects in myeloid cells or their precursors

Treatment for severe neutropenia in certain cancer patients approved by FDA

The FDA approves tbo-filgrastim for treatement of severe neutropenia in patients who have cancers other than blood or bone marrow cancers and are taking chemotherapy drugs that causes severe neutropen...

EMA Panel Recommends Approval of Loxapine for Agitation

An advisory panel to the EMA has recommended the approval of loxapine for the rapid control of agitation in patients with bipolar disorder or schizophrenia. International Approvals

New Treatment for Severe Neutropenia Approved

The U.S. Food and Drug Administration approved a drug called tbo-filgrastim to shorten bouts of severe neutropenia, a condition that leads to decreased levels of infection-fighting white blood cells (...

Neutropenia (low neutrophil count)

Neutropenia: Symptom — Overview covers definition, possible causes of a lack of certain white blood cells.

FDA Approves Adasuve (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I Disorder in Adults

MOUNTAIN VIEW, Calif., Dec. 21, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Adasuve (loxapine) Inhalation Powder 10...

Teva to commercialize Alexza Adasuve (loxapine) inhalation powder in US

Teva Pharmaceuticals USA has obtained commercialization rights to Alexza Pharmaceuticals' Adasuve (loxapine) inhalation powder 10mg in the country.

Alexza resubmits Adasuve NDA

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) jumped $1.23 (45%) to $3.97 on Friday after resubmitting an NDA to FDA for Adasuve Staccato loxapine to treat agitation in patients with schizophrenia or bipo...

FDA Approves Short-Acting Neutropenia Drug

(MedPage Today) -- The FDA has approved a short-acting formulation of granulocyte-colony stimulating factor for managing chemotherapy-induced neutropenia.

Investigation of the disposition of loxapine, amoxapine and their hydroxylated metabolites in different brain regions, CSF and plasma of rat by LC-MS/MS.

Loxapine represents an interesting example of old "new" drug and is recently drawing attention for its novel inhalation formulation for the treatment of both psychiatric and non-psychiatric disorders....

Safety and efficacy review of inhaled loxapine for treatment of agitation.

Agitation is common in patients with acute schizophrenia and bipolar disorder, and rapid and effective treatment of acute agitation is an important clinical goal. Loxapine is a first-generation antips...

Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.

Objective:  To describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (ES). Data sources:â...

Transient neutropenia in children with febrile illness and associated infectious agents: 2 years' follow-up.

The aim of the study was to identify the relationship of acquired neutropenia with childhood infections and to assess its clinical course, complications, and outcome. Children admitted to two pediatri...

In vitro aerosol characterization of Staccato(®) Loxapine.

Medicinal aerosol products (metered dose and dry powder inhalers) require characterization testing over a wide range of use and pre-operating stress scenarios in order to ensure robust product perform...